Back to Search
Start Over
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
- Source :
-
Current hematologic malignancy reports [Curr Hematol Malig Rep] 2023 Dec; Vol. 18 (6), pp. 234-242. Date of Electronic Publication: 2023 Aug 31. - Publication Year :
- 2023
-
Abstract
- Purpose of Review: While most patients with chronic myeloid leukemia (CML) present in a chronic phase and are expected to have a normal life expectancy, some patients present with or progress to a more aggressive accelerated phase (AP) or blast phase (BP) of CML. Herein, we discuss the diagnostic considerations of advanced phase CML and review its contemporary management.<br />Recent Findings: Later-generation, more potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as ponatinib may result in superior outcomes in patients with advanced phase CML. For CML-BP, combination approaches directed against the blast immunophenotype appear superior to TKI monotherapy. The role of allogeneic stem cell transplantation is controversial in CML-AP but has consistently been shown to improve outcomes for patients with CML-BP. Advanced phase CML, particularly CML-BP, remains a poor risk subtype of CML. However, novel combination approaches using later-generation TKIs are being explored in clinical trials and may lead to improved outcomes.<br /> (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Subjects :
- Humans
Protein Kinase Inhibitors adverse effects
Blast Crisis drug therapy
Fusion Proteins, bcr-abl genetics
Drug Resistance, Neoplasm genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Hematopoietic Stem Cell Transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 1558-822X
- Volume :
- 18
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Current hematologic malignancy reports
- Publication Type :
- Academic Journal
- Accession number :
- 37651057
- Full Text :
- https://doi.org/10.1007/s11899-023-00709-4